Scilex Holding Co is an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain. The company markets three FDA approved products ZTlido for postherpetic neuralgia ELYXYB for acute migraine and GLOPERBA for gout prophylaxis. It also has a pipeline of product candidates including SEMDEXA for sciatica SP-103 for acute pain and SP-104 for fibromyalgia. Revenue is generated primarily from sales of its approved products ZTlido ELYXYB and...
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | NVS | Novartis Ag | 110,466,237.30 Bn | 25.37 Mn | 2.11 Mn | - |
| 2 | GSK | GSK plc | 92,553,268.41 Bn | 11.78 Mn | 2.11 Mn | -26.01 Bn |
| 3 | LLY | ELI LILLY & Co | 900.54 Bn | 0.00 Mn | 0.00 Mn | 43.37 Bn |
| 4 | JNJ | Johnson & Johnson | 555.49 Bn | 0.00 Mn | 0.00 Mn | 54.99 Bn |
| 5 | ABBV | AbbVie Inc. | 373.61 Bn | 0.00 Mn | 0.00 Mn | 64.53 Bn |
| 6 | MRK | Merck & Co., Inc. | 279.83 Bn | 0.00 Mn | 0.00 Mn | 49.12 Bn |
| 7 | AMGN | Amgen Inc | 181.63 Bn | 0.00 Mn | 0.00 Mn | 57.32 Bn |
| 8 | GILD | Gilead Sciences, Inc. | 163.98 Bn | 0.00 Mn | 0.00 Mn | 22.17 Bn |